Activation of coagulation by a LDL-apheresis device.
LDL-apheresis often induces an almost constant and progressive increase of the differential pressure of plasma flowing through the dextran sulphate cellulose column, reducing the efficacy of the treatment. On two occasions we were able to identify a fibrin plug by immunofluorescence. Our aim was to verify the modification of some coagulation indicators in patients undergoing LDL-apheresis and whether an activation of coagulation occurs in the LDL-apheresis device. Blood samples were obtained from six patients with familial hypercholesterolaemia who were undergoing LDL-apheresis. During the same session further blood/ plasma samples were taken from the LDL-apheresis device at different sites and at different volumes of filtered blood. In patients after LDL-apheresis the following modifications were found: a 25% decrease of fibrinogen and a slight increase in F1 + 2 plasma levels. No relevant changes in thrombin-antithrombin complexes and fibrinopeptide A plasma levels were noted. In the LDL-apheresis device the main results were: (a) fibrinogen was trapped in the dextran sulphate cellulose column in the early phases; (b) activation of coagulation was recognisable in the plasma separator during the procedure and progressively increased with duration of LDL-apheresis; (c) thrombin-antithrombin complexes, formed in the plasma separator, were retained by the dextran sulphate cellulose column. In conclusion, LDL-apheresis activates coagulation in the device. Shortening cycle time or using nafamostat mesilate as an anticoagulant, could be interesting alternatives for improving the procedure.
Giansante
C
C
Institute of Clinical Medicine, University of Trieste, Italy. carlog@clmed.univ.trieste.it
Bordin
P
P
Fiotti
N
N
Calabrese
S
S
Petrucco
A
A
Da Col
P G
PG
Fonda
M
M
Cattin
L
L
D000368:Aged; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation; D001781:Blood Component Removal / Q000295:instrumentation / Q000379:methods; D002482:Cellulose; D003911:Dextrans; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010447:Peptide Hydrolases / Q000378:metabolism; D013431:Sulfates
D003911:Dextrans; D008077:Lipoproteins, LDL; D013431:Sulfates; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D005340:Fibrinogen; D002482:Cellulose; D010447:Peptide Hydrolases